Daxor director granted 2,500 stock options

Daxor Corp director Henry D. Cremisi received a grant of stock options for 2,500 shares of common stock.

Rhea-AI Filing Summary

Daxor Corp director Henry D. Cremisi received a grant of stock options for 2,500 shares of common stock. The options carry an exercise price of $10.14 per share and expire on June 23, 2031. This is a compensation-related award, not an open-market trade.

The grant is contingent on SEC approval of an amendment to the Daxor Corporation 2020 Incentive Compensation Plan. The options are scheduled to vest in three installments: 833 options on June 23, 2026, 883 on June 23, 2027, and 834 on June 23, 2028.

Insider Trade Summary

Grant/Award: 2,500 shares

Grant/Award 1 txn

Insider Cremisi Henry D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	2,500	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 2,500 contracts (Direct)

Footnotes (2)

1. F1. Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
2. F2. The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)

Key Figures

Options granted: 2,500 options Exercise price: $10.14 per share Expiration date: June 23, 2031 +5 more

8 metrics

Options granted 2,500 options Stock options grant to director Henry D. Cremisi

Exercise price $10.14 per share Conversion or exercise price for granted options

Expiration date June 23, 2031 Option term end date

Underlying shares 2,500 shares Common stock underlying the options

Post-grant derivative holdings 2,500 options Total derivative shares following transaction

First vesting installment 833 options Vest on June 23, 2026

Second vesting installment 883 options Vest on June 23, 2027

Third vesting installment 834 options Vest on June 23, 2028

Key Terms

Stock Options (right to buy), exercise price, expiration date, 2020 Incentive Compensation Plan, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: Stock Options (right to buy)"

exercise price financial

"conversion_or_exercise_price: 10.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2031-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

2020 Incentive Compensation Plan financial

"to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan")"

vesting financial

"The stock options will vest in three installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Daxor (DXR) director Henry D. Cremisi report in this Form 4?

Henry D. Cremisi reported receiving a grant of stock options for 2,500 shares of Daxor common stock. These options are a compensation award, not an open-market purchase or sale, and reflect equity-based pay rather than a change in his cash investment position.

What are the key terms of the Daxor (DXR) stock options granted to Henry D. Cremisi?

The options cover 2,500 shares of Daxor common stock at an exercise price of $10.14 per share, expiring June 23, 2031. They were granted as a compensation award and are subject to specific vesting dates and a plan amendment approval condition.

How do the Daxor (DXR) options granted to Henry D. Cremisi vest over time?

The 2,500 stock options vest in three annual installments. According to the disclosure, 833 options vest June 23, 2026, 883 vest June 23, 2027, and 834 vest June 23, 2028, creating a multi-year incentive tied to continued board service.

Are the Daxor (DXR) stock options to Henry D. Cremisi immediately effective?

No, the option grant is contingent on SEC approval to amend the Daxor Corporation 2020 Incentive Compensation Plan. This means the award depends on regulatory clearance of the plan amendment before it is fully effective under the described terms.

Did Henry D. Cremisi buy or sell Daxor (DXR) shares on the market in this filing?

No market buy or sale occurred. The Form 4 reports a grant of stock options as compensation, coded as an acquisition (A) of derivative securities. It does not show open-market purchases or sales of Daxor common stock by the director.

What is Henry D. Cremisi’s option position after this Daxor (DXR) grant?

After the reported grant, Cremisi holds 2,500 stock options linked to Daxor common stock, as shown by the total shares following the transaction. These options are subject to staged vesting dates and an expiration on June 23, 2031.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 05:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cremisi Henry D.

(Last) (First) (Middle)

109 MECO LANE

(Street)

OAK RIDGE, TENNESSEE 37830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DAXOR CORP [ DXR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$10.14	06/23/2026(1)		A		2,500		(2)	06/23/2031	COMMON STOCK	2,500	$0	2,500	D

Explanation of Responses:

1. Stock options granted on June 23, 2026 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").

2. The stock options will vest in three installments on June 23, 2026 (833), June 23, 2027 (883) and June 23, 2028 (834)

	/s/ Henry Cremisi	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)